Global Markets for Implantable Biomaterials
The global market for implantable biomaterials in 2013 was worth nearly $75.1 billion. This market is expected to grow at a compound annual growth rate (CAGR) of 6.7% between 2014 and 2019. This will result in $79.1 billion in 2014 and $109.5 billion global market in 2019.
- An overview of the global market for biomaterials used in medical applications.
- Analyses of global market trends, with data from 2013 and 2014, and projections of CAGRs through 2019.
- Segmentation of the biomaterials based on the materials from which they are made including metallic, ceramic, polymeric, natural and composite materials.
- Segmentation based on therapeutic or application area including orthopaedic, cardiovascular, dental, immunology and infection, pulmonary/respiratory disease, plastic surgery, ophthalmology, oncology, neurology, and more.
- Comprehensive profiles of leading companies in the industry.
This market research report focuses on the global market for medical biomaterials by geographic region and by market segment, and also provides an in-depth discussion and analysis of the application of biomaterials and a review of new and developing technology platforms. This report also examines companies that are actively developing and marketing medical biomaterials around the world. Detailed tables and charts with sales forecasts and market share data are also included.
Products that are used as biomaterials can be segmented by the materials from which they are made; for example:
In addition to the segmentation by material type, medical biomaterials can also be examined by application/therapeutic area as follows:
- Immunology and infection.
- Pulmonary/respiratory disease.
- Plastic surgery.
- Endocrinology and metabolic diseases.
- Dermatology and wound care.
- Oto-Rhino-Laryngology (ORL).
The global market for medical biomaterials has been estimated at $48 billion in 2013, and is expected to more than double by 2019, reaching $102.5 billion. The growth represents a compound annual growth rate (CAGR) of by the end of the forecast period.
In 2013, the cardiovascular biomaterial segment represented the largest single market segment, accounting for 34.5% of the global biomaterial market, followed by the orthopedic segment. Plastic surgery and wound healing applications are expected to experience the highest growth in the coming years.
North America is the largest market for biomaterials and is expected to grow at CAGR of 5.2% from 2014 to 2019 due to an increase in the aging population. Due to rising awareness of biomaterial products in Asia, and increased partnerships and collaborations, the Asian market is expected to grow at a CAGR of 21.5% from 2014 to 2019.
PAUL TAYLOR is an independent market researcher and analyst focused on the medical industry working on projects for over 20 years for a variety of prestigious clients including Agilent & Philips Medical Systems, Biomatrix, Inc (Genzyme Corporation), GE Medical Systems (Multiple Projects), Amersham Pharmacia Biotech Limited, Amersham Pharmacia Biotech Limited and Baxter Heathcare. He previously worked for multinational medical device and pharmaceutical companies including Bristol-Myers Squibb, Johnson & Johnson and Pfizer on developing and implementing strategic business and marketing plans. His predictive analytics knowledge and models of market research data have been used for biopharmaceutical and biotechnology clients. He has a bachelor's degree and Ph.D. degree in biochemistry from the University of Liverpool and an MBA degree for Oxford Brookes University.
- Antifungal Drugs: Technologies and Global Markets (PHM029G)
- Latest Development, Product Innovations and Treatments for Diabetes (HLC249A)
- Latest Innovations in Medical Device Technologies (HLC234A)
- Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy (BIO162A)
- Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success In Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancers (BIO171A)